Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin

Journal of Chemotherapy

Volumn 17, Issue 2, 2005, Pages 138-142

  Montanari, M P ^a   Ferrante, L ^a   Tili, E ^a   Cochetti, I ^a   Rossi, V ^b   Varaldo, P E ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b ACRAF SpA   (Italy)

Author keywords

Breakpoints; Discrepancy rates; Disk diffusion susceptibility testing; Error rate bounded method; Fluoroquinolones; Interpretive criteria; Prulifloxacin; Quinolone antibiotics; Ulifloxacin

Indexed keywords

CIPROFLOXACIN; DRUG METABOLITE; PRODRUG; PRULIFLOXACIN; ULIFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL LABORATORY; CONTROLLED STUDY; DIFFUSION; DRUG SENSITIVITY; ENTEROBACTERIACEAE; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 19544392297     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.2.138     Document Type: Article

References (17)

1. Ozaki M, Matsuda M, Tomii Y et al. In vitro antibacterial activity of a new quinolone, NM441. Antimicrob Agents Chemother 1991; 35 (12): 2490-2495.
2. Ozaki M, Matsuda M, Tomii Y et al. In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob Agents Chemother 1991; 35 (12): 2496-2499.
3. Nakashima M, Uematsu T, Kosuge K et al. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J Clin Pharmacol 1994; 34 (9): 930-937.
4. Yoshida T, Mitsuhashi S. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob Agents Chemother 1993; 37 (4): 793-800.
5. Montanari MP, Mingoia M, Varaldo PE In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob Agents Chemother 2001; 45 (12): 3616-3622.
6. Prats G, Roig C, Mirò E, Navarro F, Mirelis B. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur J Clin Microbiol Infect Dis 2002; 21 (4): 328-334.
7. Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64 (19), 2221-2234.
8. Fattore C, Cipolla G, Gatti G et al. Pharmacokinetic interactions between theophylline and prulifloxacin in healthy volunteers. Clin Drug Invest 1998; 16 (5): 387-392.
9. Picollo R, Brion N, Gualano V et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneim-Forsch/Drug Res 2003; 53 (3): 201-205.
10. Angelini ACRAF S.p.A. Investigator's brochure: Unidrox® prulifloxacin 600 mg tablets. Rome: ACRAF S.p.A. 2004.
11. th ed. Approved standard M7-A6. Wayne, PA: NCCLS 2003.
12. th ed. Approved standard M2-A8. Wayne, PA: NCCLS 2003.
13. nd ed. Approved standard M23-A2. Wayne, PA: NCCLS 2001.
14. Fuchs PC, Barry AL, Brown SD. Selection of zone size interpretive criteria for disk diffusion susceptibility tests of three antibiotics against Streptococcus pneumoniae, using the new guidelines of the National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother 2002; 46 (2): 398-401.
15. Metzler DM, DeHaan RM. Susceptibility test of anaerobic bacteria: statistical and clinical considerations. J Infect Dis 1974; 130 (6): 588-594.
16. Brunden MN, Zurenko GE, Kapik B. Modification of the error-bounded classification scheme for use with two MIC breakpoints. Diagn Microbiol Infect Dis 1992; 15 (2): 135-140.
17. National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and quality control parameters. Approved standard M23-A. Villanova. PA: NCCLS 1994.